Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Fusion protein or fusion polypeptide
Reexamination Certificate
2011-08-09
2011-08-09
Chen, Stacy B (Department: 1648)
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Fusion protein or fusion polypeptide
C424S186100, C424S209100, C435S069100
Reexamination Certificate
active
07993652
ABSTRACT:
The present invention relates to an influenza antigen, comprising a fusion product of at least the extracellular part of a conserved influenza membrane protein or a functional fragment thereof and a presenting carrier, which may be a presenting (poly)peptide or a non-peptidic structure, such as glycans, peptide mimetics, synthetic polymers. The invention further relates to a vaccine against influenza, comprising at least an antigen of the invention, optionally in the presence of one or more excipients. The invention also relates to use of the antigen, a method for preparing the antigen and acceptor cells expressing the antigen.
REFERENCES:
patent: 3919044 (1975-11-01), Melnick et al.
patent: 5691189 (1997-11-01), Kurtz et al.
patent: 5843446 (1998-12-01), Ladd et al.
patent: 5871747 (1999-02-01), Gengoux-Sedlik et al.
patent: 6169175 (2001-01-01), Frace et al.
patent: 49273/90 (1990-08-01), None
patent: WO 92/22575 (1992-12-01), None
patent: WO 94/06472 (1994-03-01), None
patent: WO 98/23735 (1998-06-01), None
patent: WO 99/07839 (1999-02-01), None
patent: WO 01/49886 (2001-07-01), None
Alford et al., Proc Soc Exp Biol Med. 122(3):800-804 (1966).
Allen et al., “Influenza Virus RNA Segment 7 Has the Coding Capacity for Two Polypeptides”, Virology, 107:548-551 (1980).
Arnon, et al., “Synthetic recombinant vaccines against viral agents” Int Arch Allergy Immunol 108(4):321-326 (1995).
Asanuma, et al., “Cross-protection against influenza virus infection in mice vaccinated by combined nasal/subcutaneous administration” Vaccine 1301:3-5 (1995).
Bachmayer, et al., “Potency of influenza vaccines: mouse protection experiments in correlation to field studies in man” Dev. Biol Stand 28:336-339 (1975).
Baez, et al., “Gene composition of high-yielding influenza vaccine strains obtained by recombination” J Infect Dis 141:362-365 (1980).
Bastin, et al., “Use of synthetic peptides of influenza nucleoprotein to define epitopes recognized by class I-restricted cytotoxic T lymphocytes” J Exp. Med. 165:1508-1523 (1987)I.
Bednarek, et al., “The minimum peptide from the influenza-virus matrix protein. Extra and intracellular loading of HLA-A2” J Immunol 147:4047-4053 (1991).
Ben-Ahmeida, et al., “IgG subclass response and protection against challenge following immunisation of mice with various influenza A vaccines” J Med Microbiol 40(4):261-269 (1994).
Berendt, et al., “Evaluation of commercially prepared vaccines for experimentally induced type A/New Jersey/8/76 influenza virus infections in mice and squirrel monkeys” J. Infect Dis 136 Suppl:S712-717(1977).
Betakova, et al., “The NB protein is an integral component of the membrane of influenza B virus” J Gen Virol 77(Pt 11);2689-2694 (1996).
Black, R.A. et al., “Antibody Response to the M2 Protein of Influenza A Virus Expressed in Insect Cells”, Journal of General Virology 74:143-146 (1993).
Bodmer, et al., “Enhanced Recognition of a Modified Peptide Antigen by Cytotoxic T Cells Specific for Influenza Nucleoprotein” Cell 52:253-258 (1988).
Borisova et at, “Recombinant Core Particles of Hepatitis B Virus Exposing Foreign Antigenic Determinants on Their Surface,” FEBS Letters 259: 121-124 (1989).
Bottex, et al., “Comparative immunogenicity of live influenza viruses and their solubilized neuraminidases: results, of mouse protection experiments” Arch Virol 70(2):83-89 (1981).
Brassard, et al., “Influenza B virus NB glycoprotein is a component of the virion” Virology 220(2): 350-360 (1996).
Brett, et al., “Human T Cell Recognition of Influenza A Nucleoprotein. Specificity and Genetic Restriction of Immunodominant T Helper Cell Epitopes” J Immunol 147:984-991 (1991).
Brown et al., “Foreign Epitopes in Immunodominant Regions of Hepatitis B Core Particles are Highly Immunogenic and Conformationally Restricted,” Vaccine 9:595-601 (1991).
Ceppelini, et al., “Binding of labelled influenza matrix peptide to HLA DR in living B lymphoid cells” Nature 339, 392-394 (1989).
Cerundolo, et al., “CD8 independence and specificity of cytotoxic T-lymphocytes restricted by HLA Aw68.1” Proc Roy Soc Lond Series B Biol Sci 244:169-177 (1991).
Charbit et al., “Probing the Topology of a Bacterial Membrane Protein by Genetic Insertion of a Foreign Epitope; Expression at the Cell Surface,” EMBO J. 5:3029-3037 (1986).
Charbit et al., “Presentation of Two Epitopes of the preS2 Region of Hepatitis B Virus on Live Recombinant Bacteria”, J. Immunol., 139:1658-1664 (1987).
Chen, et al., “Protection against influenza B virus infection by immunization with DNA vaccines” Vaccine 19:1446-1455 (2001).
Clarke et al., “Presentation and immunogenicity of Viral Epitopes on the Surface of a Hybrid Hepatitis B Virus Core Particles Produced in Bacteria,” J. General Virology 71: 1109-1117 (1990).
Clarke et al, “Improved Immunogenicity of a Peptide Epitope After Fusion to Hepatitis B Core Protein,” Nature 330:381-384 (1987).
Cox et al., “Identification of Sequence Changes in the Cold-Adapted, Live Attenuated Influenza Vaccine Strain, A/Ann Arbor/6/60(H2N2)”, Virology 167:554-567 (1988).
Cruse, et al., Illustrated Dictionary of Immunology, CRC Press, Boca Raton, pp. 46 and 229 (1995).
Deck, et al., “Characterization of humoral immune responses induced by an influenza hemagglutinin DNA vaccine” Vaccine 15(1):71-78 (1997).
De Filette et al., “Universal influenza A vaccine: optimization of M2-based constructs” Virology. Jun. 20, 337(1):149-161 (2005).
De Filette et al., “The universal influenza vaccine M2e-HBc administered intranasally in combination with the adjuvant CTA1-DD provides complete protection” Vaccine. Jan. 30, 2006a; 24(5):544-551.
De Filette et al., “Improved design and intranasal delivery of an M2e-based human influenza A vaccine” Vaccine. Nov. 10, 2006b; 24(44-46);6597-6601.
De Filette et al., “An influenza A vaccine based on tetrameric ectodomain of matrix protein 2” J Biol Chem. Apr. 25, 2008a; 283(17):11382.
De Filette et al., “Universal influenza A M2e-HBc vaccine protects against disease even in the presence of pre-existing anti-HBc antibodies” Vaccine. Dec. 2, 2008b; 26(51):6503-6507.
de Haan, et al., “Mucosal immunoadjuvant activity of liposomes: induction of systemic IgG and secretory IgA responses in mice by intranasal immunization with an influenza subunit vaccine and coadministered liposomes” Vaccine 13(2):155-162 (1995).
Deroo, et al., “Recombinant neuraminidase vaccine protects against lethal influenza” Vaccine 14(6):561-569 (1996).
de Velasco, et al., “Synthetic peptides representing T-cell epitopes act as carriers in pneumococcal polysaccharide conjugate vaccines” Infect Immun 63(3):961-968 (1995).
DiBrino, et al., “HLA-A1 and HLA-A3 T-cell epitopes derived from influenza-virus proteins predicted from peptide binding motifs” J Immunol 151:5930-5935 (1993).
Dong, et al., “An HLA-B35-restricted epitope modified at an anchor residue results in an antagonist peptide” Eur J Immunol 26:335-339 (1996).
Dorland's Illustrated Dictionary, 1994, 28th ed., Philadelphia; WB Sauders Company, p. 1254.
Dorland's Illustrated Medical Dictionary, 27.sup.th ed., W.B. Saunders Company, Philadelphia, pp. 57, 1746, and 1799 (1988).
Estabrook, et al., “Monoclonal antibodies: their importance to surgeons” J. Invest. Surg. 2(3): 211-222 (1989) abstract only.
Eliasson et al., “CTA1-M2e-DD: a novel mucosal adjuvant targeted influenza vaccine” Vaccine. Feb. 26, 2008; 26(9):1243-1252.
Ernst et al., “Protection against H1, H5, H6 and H9 influenza A infection with liposomal matrix 2 epitope vaccines” Vaccine. Jun. 12, 2006; 24(24):5158.
Fan et al., “Preclinic
Fiers Walter
Jou Willy Min
Neirynck Sabine
Chen Stacy B
FVlaams Interuniversitair Instituut Voors Biotechnologie
Husch & Blackwell LLP
LandOfFree
Immunoprotective influenza antigen and its use in vaccination does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunoprotective influenza antigen and its use in vaccination, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunoprotective influenza antigen and its use in vaccination will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2793201